Document resource
Background and Importance Patient-Reported Outcomes (PROs) have become valuable tools for assessing the quality of life as perceived by patients. Validated instruments such as the Psoriasis Symptoms and Signs Diary (PSSD) and EQ-5D-5L allow for standardised evaluation and support a multidisciplinary, patient-focused approach, enabling treatment optimisation.Aim and Objectives The objectives are to evaluate disease control in patients with moderate-to-severe psoriasis treated with biologics and to analyse discrepancies between PROs and the Psoriasis Area and Severity Index (PASI). Additionally, to describe the profile of poorly controlled patients and identify factors related to therapeutic response.Material and Methods This is a single-centre, prospective, observational, and cross-sectional study, conducted between January and July 2025. It included patients aged ≥18 years with moderate-to-severe psoriasis receiving biologic therapy for at least 6 months. Patients with language barriers or lost to follow-up were excluded.Collected variables included demographics (age, sex), treatment-related data (duration, current therapy, treatment line), and efficacy measures (PASI, EQ-5D-5L). Good disease control was defined as PSSD < 20 or PASI < 10. A protocol was established with dermatology so that patients with PSSD > 20 were referred by the pharmacist for reassessment. Statistical analysis was performed using SPSS, with a significance level set at p < 0.05.Results A total of 44 patients were included (54.5% male, 45.5% female; median age: 48 years). The median treatment duration was 25 months. 15 patients (34.1%) had a PSSD > 20 and were referred. Among them, 61.4% were on adalimumab, and 54.5% were on first-line therapy. The median PASI score at the time of referral was 1. No significant correlation was found between PASI and PSSD (rho = 0.146; p = 0.487), nor were statistically significant associations observed with variables such as age (p=0.853), sex (Yates correction = 1), treatment or treatment line (Yates correction =1), treatment duration (p= 0.647), or EQ-5D-5L (p= 0.153).Conclusion and Relevance Although PASI scores were low, nearly 40% of patients showed poor control according to the PSSD, highlighting a discrepancy between clinical assessment and patient perception. Incorporating the PSSD into routine clinical practice may facilitate the early detection of inadequate treatment response and support its optimisation.Conflict of Interest No conflict of interest